Δημοσίευση στις 2020 Mar 2 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/32135273/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=1
, Apostolos Tzikas
, Emmanouil Vavouranakis
, Dimitrios Nikas
, Georgios Katsimagklis
, Eleni Koroboki
, Antonis S Manolis
, Haralampos Milionis
, Konstantinos Papadopoulos
, Skevos Sideris
, Konstantinos Spengos
, Konstantinos Toutouzas
, Dimitrios Tziakas
, Sofia Vassilopoulou
, Ioannis Kanakakis
, Konstantinos Vemmos
, Konstantinos Tsioufis
Patent foramen ovale (PFO) is a frequent echocardiographic finding and can be found in approximately 15-25% of the general population1 (Figure 1). The incidence of PFO is 2- to 3-fold higher in patients with stroke of undetermined etiology compared to the general population, a finding that implies a causative role of PFO in patients with stroke of undetermined etiology 2,3. In this context, percutaneous PFO closure has been increasingly used as a strategy to prevent stroke recurrence in patients with stroke of no apparent cause 4. During the recent years, evidence about the efficacy and safety of this strategy has accumulated through observational studies and well-designed randomized trials5-12.This paper is a consensus statement of expert panelists from the Hellenic Stroke Organization (HSO) and the Working Group for Stroke of the Hellenic Society of Cardiology (HSC) for the secondary prevention in patients with embolic stroke of undetermined source and PFO. It aims to assist clinicians, patients/families and the Hellenic regulatory authorities to design optimal secondary prevention strategies for this patient population. The recommendations of the panelists are summarized in Table 1.
PFO closure; Patent foramen ovale; embolic stroke of undetermined source.
Copyright © 2020 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
Arch Cardiovasc Dis. 2019 Aug-Sep;112(8-9):532-542. doi: 10.1016/j.acvd.2019.06.002. Epub 2019 Aug 1.
Arch Cardiovasc Dis. 2019.
Reprint of : Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
Rev Neurol (Paris). 2020 Jan-Feb;176(1-2):53-61. doi: 10.1016/j.neurol.2019.10.002. Epub 2019 Nov 28.
Rev Neurol (Paris). 2020.
Recurrent Stroke in a Young Patient with Embolic Stroke of Undetermined Source and Patent Foramen Ovale: Quo Vadis?
Case Rep Neurol. 2020 Jan 29;12(1):45-49. doi: 10.1159/000505180. eCollection 2020 Jan-Apr.
Case Rep Neurol. 2020.
Free PMC article.
Patent Foramen Ovale and Stroke-Current Status.
J Stroke. 2015 Sep;17(3):229-37. doi: 10.5853/jos.2015.17.3.229. Epub 2015 Sep 30.
J Stroke. 2015.
Free PMC article.
Amplatzer patent foramen ovale occluder: safety and efficacy.
Expert Rev Med Devices. 2019 Mar;16(3):173-182. doi: 10.1080/17434440.2019.1581060. Epub 2019 Feb 18.
Expert Rev Med Devices. 2019.